(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.
Oct 31, 2011
0
0
People who suffer from acute stroke or Transient Ischaemic Attack (TIA, a mini stroke) could get better treatment in the future thanks to the expansion of a large clinical trial of a new combination of drugs led by researchers ...
Oct 17, 2011
0
0
(AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.
Oct 7, 2011
0
0
Researchers are working to discover how genes interact with each other to lead to cancer progression. This research is expected to lead the way toward the discovery of new targeted therapies against breast cancer, according ...
Sep 15, 2011
0
0
Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings ...
Sep 12, 2011
0
0
NYU School of Medicine researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults ...
Sep 1, 2011
0
0
A new drug, rilpivirine, can add powerfully to the combination of medications used to control HIV for first-time patients, researchers conclude in Friday's issue of The Lancet.
Jul 15, 2011
0
0
(Medical Xpress) -- The full results of a trial show that people with chronic kidney disease can reduce their heart risk by taking a combination drug that lowers levels of ‘bad’ cholesterol.
Jun 13, 2011
0
0
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...
Jun 6, 2011
0
0
Faults in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to research at Newcastle University.
Jun 6, 2011
0
0
